However, mass spectrometry analyses of the IRF4 peptide sequence encompassing 90% coverage failed to detect acetylation events at lysine residues at position 123 (K123) or position 59 (K59) (Table 1), suggesting that the most frequently observed mutations in IRF4 seen in patients with MM did not directly alter acetylation targets. The gene discussed is IRF4; the disease is Miyoshi myopathy.